SI2535358T1 - Radioactive metal-labeled anti-cadherin antibody - Google Patents

Radioactive metal-labeled anti-cadherin antibody Download PDF

Info

Publication number
SI2535358T1
SI2535358T1 SI201131433T SI201131433T SI2535358T1 SI 2535358 T1 SI2535358 T1 SI 2535358T1 SI 201131433 T SI201131433 T SI 201131433T SI 201131433 T SI201131433 T SI 201131433T SI 2535358 T1 SI2535358 T1 SI 2535358T1
Authority
SI
Slovenia
Prior art keywords
antibody
cadherin
nite
radioactive metal
cancer
Prior art date
Application number
SI201131433T
Other languages
English (en)
Slovenian (sl)
Inventor
Akihiro Hino
Akio Nagano
Masahiko Watanabe
Tadasi Matsuura
Hirokazu Satoh
Fumiko Nomura
Katsuyuki Mitomo
Original Assignee
Fujifilm Ri Pharma Co., Ltd.
Perseus Proteomics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Ri Pharma Co., Ltd., Perseus Proteomics Inc. filed Critical Fujifilm Ri Pharma Co., Ltd.
Publication of SI2535358T1 publication Critical patent/SI2535358T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201131433T 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody SI2535358T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010028028 2010-02-10
EP11742267.5A EP2535358B1 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
PCT/JP2011/052759 WO2011099524A1 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体

Publications (1)

Publication Number Publication Date
SI2535358T1 true SI2535358T1 (en) 2018-03-30

Family

ID=44367795

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131433T SI2535358T1 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody

Country Status (22)

Country Link
US (2) US8815211B2 (enExample)
EP (1) EP2535358B1 (enExample)
JP (2) JP5380553B2 (enExample)
KR (1) KR101900110B1 (enExample)
CN (1) CN102892787B (enExample)
AU (1) AU2011215267B2 (enExample)
BR (1) BR112012020116B8 (enExample)
CA (1) CA2789310C (enExample)
CY (1) CY1120012T1 (enExample)
DK (1) DK2535358T3 (enExample)
ES (1) ES2656168T3 (enExample)
HR (1) HRP20180293T1 (enExample)
HU (1) HUE037817T2 (enExample)
LT (1) LT2535358T (enExample)
NO (1) NO2535358T3 (enExample)
PL (1) PL2535358T3 (enExample)
PT (1) PT2535358T (enExample)
RS (1) RS57008B1 (enExample)
RU (1) RU2577125C2 (enExample)
SG (1) SG183272A1 (enExample)
SI (1) SI2535358T1 (enExample)
WO (1) WO2011099524A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2535358T3 (enExample) * 2010-02-10 2018-05-19
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
US20150031988A1 (en) * 2011-09-16 2015-01-29 Eri Takeuchi Nano-particles for internal radiation therapy of involved area, and therapy system
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
ES2829597T3 (es) * 2013-02-15 2021-06-01 Perseus Proteomics Inc Anticuerpo humanizado anti-CDH3, conjugado de fármaco del mismo y utilización del mismo
WO2015181882A1 (ja) * 2014-05-27 2015-12-03 株式会社島津製作所 分岐型両親媒性ブロックポリマーを用いた分子集合体及び薬剤搬送システム
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
WO2017120557A1 (en) * 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
CA3031198A1 (en) * 2016-08-19 2018-02-22 Fujifilm Toyama Chemical Co., Ltd. Composition containing buffer
EP3551745A4 (en) 2016-12-12 2020-07-15 Xcella Biosciences, Inc. SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS
RU2657761C1 (ru) * 2017-05-29 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ диагностики опухоли
CA3156776A1 (en) 2019-11-08 2021-05-14 xCella Biosciences, Inc. Apparatus and methods for laser-based single cell recovery from microcapillary arrays
CN122206699A (zh) * 2023-10-26 2026-06-12 株式会社英仙蛋白质科学 225Ac标记的抗CDH3抗体
AU2024386376A1 (en) 2023-11-21 2026-05-28 3B Pharmaceuticals Gmbh P-cadherin ligands
CN121426958B (zh) * 2025-12-31 2026-03-24 北京大学人民医院 一种抗cdh3纳米抗体与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4917878A (en) * 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000026672A1 (en) * 1998-10-30 2000-05-11 Georgetown University Diagnosis of breast cancer using antibody against cadherin-11
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
CA2445611A1 (en) 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005514409A (ja) * 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
CA2487692A1 (en) * 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
KR20080083068A (ko) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
EP2004687A1 (en) * 2006-02-28 2008-12-24 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-cdh3 antibodies
CA2729403A1 (en) * 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
CN102781964B (zh) * 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
NO2535358T3 (enExample) * 2010-02-10 2018-05-19

Also Published As

Publication number Publication date
JP5848737B2 (ja) 2016-01-27
EP2535358B1 (en) 2017-12-20
CA2789310A1 (en) 2011-08-18
CN102892787B (zh) 2015-04-29
BR112012020116B1 (pt) 2021-12-14
ES2656168T3 (es) 2018-02-23
LT2535358T (lt) 2018-03-26
NO2535358T3 (enExample) 2018-05-19
HUE037817T2 (hu) 2018-09-28
CA2789310C (en) 2018-01-09
US20140328754A1 (en) 2014-11-06
EP2535358A1 (en) 2012-12-19
PL2535358T3 (pl) 2018-05-30
US8815211B2 (en) 2014-08-26
KR20120115995A (ko) 2012-10-19
US20130071324A1 (en) 2013-03-21
RS57008B1 (sr) 2018-05-31
EP2535358A4 (en) 2013-07-10
CY1120012T1 (el) 2018-12-12
RU2012138459A (ru) 2014-03-20
CN102892787A (zh) 2013-01-23
JPWO2011099524A1 (ja) 2013-06-13
EP2535358A9 (en) 2014-03-26
AU2011215267B2 (en) 2016-07-07
PT2535358T (pt) 2018-02-23
WO2011099524A1 (ja) 2011-08-18
BR112012020116A2 (pt) 2020-08-18
KR101900110B1 (ko) 2018-09-18
RU2577125C2 (ru) 2016-03-10
DK2535358T3 (en) 2018-02-05
AU2011215267A1 (en) 2012-09-06
JP2014012731A (ja) 2014-01-23
HRP20180293T1 (hr) 2018-03-23
JP5380553B2 (ja) 2014-01-08
SG183272A1 (en) 2012-09-27
BR112012020116B8 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
HRP20180293T1 (hr) Anti-kadherin antitijelo obilježeno radioaktivnim metalom
Verel et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET
Maecke et al. 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy
Isabel M. Prata Gallium-68: a new trend in PET radiopharmacy
Liu et al. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals
AU760854B2 (en) Use of bi-specific antibodies for pre-targeting diagnosis and therapy
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
Simecek et al. Tailored gallium (III) chelator NOPO: synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging
US7052872B1 (en) Bi-specific antibodies for pre-targeting diagnosis and therapy
NZ243099A (en) Antigen binding protein containing three or four fab fragments bound to a maleimide cross linker, methods of therapy and diagnosis of cancer
Mizuno et al. Purification-free method for preparing technetium-99m-labeled multivalent probes for enhanced in vivo imaging of saturable systems
Scott Wilbur Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides
Rogers et al. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate
HRP20191620T1 (hr) Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka
JPH02152956A (ja) 隣接基放射性金属キレート生成化合物
Ma et al. Macrobicyclic cage amine ligands for copper radiopharmaceuticals: a single bivalent cage amine containing two Lys3-bombesin targeting peptides
Pandya et al. New bifunctional chelator for 64Cu-immuno-positron emission tomography
Melis et al. Bifunctional chelators for radiorhenium: Past, present and future outlook
Fersing et al. AAZTA-derived chelators for the design of innovative radiopharmaceuticals with theranostic applications
JP2023541601A5 (enExample)
RU2205187C2 (ru) Пептиды, связывающиеся с рецептором кальцитонина
Gomez et al. Synthesis and Evaluation of Diastereoisomers of 1, 4, 7-Triazacyclononane-1, 4, 7-tris-(glutaric acid)(NOTGA) for Multimeric Radiopharmaceuticals of Gallium
Postema et al. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma
Lee et al. In vitro and in vivo evaluation of structure-stability relationship of 111In-and 67Ga-labeled antibody via 1B4M or C-NOTA chelates
Luo et al. An 125I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo